Chengdu Olymvax Biopharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Chengdu Olymvax Biopharmaceuticals has a total shareholder equity of CN¥907.7M and total debt of CN¥299.8M, which brings its debt-to-equity ratio to 33%. Its total assets and total liabilities are CN¥1.6B and CN¥686.4M respectively.
Key information
33.0%
Debt to equity ratio
CN¥299.83m
Debt
Interest coverage ratio | n/a |
Cash | CN¥322.32m |
Equity | CN¥907.69m |
Total liabilities | CN¥686.45m |
Total assets | CN¥1.59b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 688319's short term assets (CN¥884.2M) exceed its short term liabilities (CN¥421.3M).
Long Term Liabilities: 688319's short term assets (CN¥884.2M) exceed its long term liabilities (CN¥265.2M).
Debt to Equity History and Analysis
Debt Level: 688319 has more cash than its total debt.
Reducing Debt: 688319's debt to equity ratio has increased from 7.6% to 33% over the past 5 years.
Debt Coverage: 688319's debt is not well covered by operating cash flow (4%).
Interest Coverage: Insufficient data to determine if 688319's interest payments on its debt are well covered by EBIT.